newsfilter
← Latest News
Business Wire·

Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in China

PRINCETON, N.J. & NANJING, China--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb’s biologic medicine, Orencia® (abatacept), for the treatment of rheumatoid arthritis. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.